Do analysts prefer GMTX or RDY?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Dr. Reddy's Laboratories 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Do analysts prefer GMTX or ELAN?

Elanco Animal Health has a consensus price target of $28.55, indicating a potential upside of 14.46%. Given Elanco Animal Health's stronger consensus rating and higher possible upside, analysts plainly believe Elanco Animal Health is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Elanco Animal Health 1 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.77

Do analysts prefer GMTX or ARWR?

Arrowhead Pharmaceuticals has a consensus target price of $87.27, indicating a potential upside of 3.91%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Arrowhead Pharmaceuticals is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Arrowhead Pharmaceuticals 1 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.69

Which has higher valuation & earnings, SMMT or GMTX?

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Summit Therapeutics N/A N/A -$1.08B -$1.60 N/A Gemini Therapeutics N/A N/A -$71.87M -$1.00 N/A

Is SMMT or GMTX more profitable?

Gemini Therapeutics' return on equity of -38.78% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Summit Therapeutics N/A -291.24% -243.07% Gemini Therapeutics N/A -38.78% -35.88%

Do analysts rate KRYS or GMTX?

Krystal Biotech currently has a consensus target price of $340.56, indicating a potential downside of 9.20%. Given Krystal Biotech's stronger consensus rating and higher possible upside, research analysts plainly believe Krystal Biotech is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Krystal Biotech 0 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.83 Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Gemini Therapeutics (GMTX) Competitors

$74.95 +1.81 (+2.47%)

As of 07/1/2026

Compare

GMTX vs. RDY, ELAN, ARWR, SMMT, and KRYS

Should you buy Gemini Therapeutics stock or one of its competitors? MarketBeat compares Gemini Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Gemini Therapeutics include Dr. Reddy's Laboratories (RDY), Elanco Animal Health (ELAN), Arrowhead Pharmaceuticals (ARWR), Summit Therapeutics (SMMT), and Krystal Biotech (KRYS). These companies are all part of the "pharmaceutical products" industry.

How does Gemini Therapeutics compare to Dr. Reddy's Laboratories?

Gemini Therapeutics (NASDAQ:GMTX) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Gemini Therapeutics has a beta of -0.12, meaning that its stock price is 112% less volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market.

In the previous week, Dr. Reddy's Laboratories had 2 more articles in the media than Gemini Therapeutics. MarketBeat recorded 2 mentions for Dr. Reddy's Laboratories and 0 mentions for Gemini Therapeutics. Gemini Therapeutics' average media sentiment score of 0.00 beat Dr. Reddy's Laboratories' score of -0.23 indicating that Gemini Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Gemini Therapeutics	Neutral
Dr. Reddy's Laboratories	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Dr. Reddy's Laboratories has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A
Dr. Reddy's Laboratories	$3.58B	3.35	$456M	$0.58	24.81

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Gemini Therapeutics' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 12.34% beat Gemini Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gemini Therapeutics	N/A	-38.78%	-35.88%
Dr. Reddy's Laboratories	12.90%	12.34%	8.24%

75.4% of Gemini Therapeutics shares are held by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. 12.9% of Gemini Therapeutics shares are held by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Dr. Reddy's Laboratories beats Gemini Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Gemini Therapeutics compare to Elanco Animal Health?

Gemini Therapeutics (NASDAQ:GMTX) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations and risk.

Gemini Therapeutics has a beta of -0.12, meaning that its share price is 112% less volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.68, meaning that its share price is 68% more volatile than the broader market.

Elanco Animal Health has a consensus price target of $28.55, indicating a potential upside of 14.46%. Given Elanco Animal Health's stronger consensus rating and higher possible upside, analysts plainly believe Elanco Animal Health is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

75.4% of Gemini Therapeutics shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 12.9% of Gemini Therapeutics shares are held by company insiders. Comparatively, 1.1% of Elanco Animal Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Elanco Animal Health had 2 more articles in the media than Gemini Therapeutics. MarketBeat recorded 2 mentions for Elanco Animal Health and 0 mentions for Gemini Therapeutics. Elanco Animal Health's average media sentiment score of 1.13 beat Gemini Therapeutics' score of 0.00 indicating that Elanco Animal Health is being referred to more favorably in the news media.

Company	Overall Sentiment
Gemini Therapeutics	Neutral
Elanco Animal Health	Positive

Gemini Therapeutics has higher earnings, but lower revenue than Elanco Animal Health. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A
Elanco Animal Health	$4.72B	2.64	-$232M	-$0.50	N/A

Gemini Therapeutics has a net margin of 0.00% compared to Elanco Animal Health's net margin of -4.95%. Elanco Animal Health's return on equity of 7.42% beat Gemini Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gemini Therapeutics	N/A	-38.78%	-35.88%
Elanco Animal Health	-4.95%	7.42%	3.66%

Summary

Elanco Animal Health beats Gemini Therapeutics on 13 of the 16 factors compared between the two stocks.

How does Gemini Therapeutics compare to Arrowhead Pharmaceuticals?

Gemini Therapeutics (NASDAQ:GMTX) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

In the previous week, Arrowhead Pharmaceuticals had 12 more articles in the media than Gemini Therapeutics. MarketBeat recorded 12 mentions for Arrowhead Pharmaceuticals and 0 mentions for Gemini Therapeutics. Arrowhead Pharmaceuticals' average media sentiment score of 0.81 beat Gemini Therapeutics' score of 0.00 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Gemini Therapeutics	Neutral
Arrowhead Pharmaceuticals	Positive

Gemini Therapeutics has a beta of -0.12, meaning that its share price is 112% less volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.26, meaning that its share price is 26% more volatile than the broader market.

Arrowhead Pharmaceuticals has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Arrowhead Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A
Arrowhead Pharmaceuticals	$829.45M	14.26	-$1.63M	-$2.15	N/A

Arrowhead Pharmaceuticals has a consensus target price of $87.27, indicating a potential upside of 3.91%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Arrowhead Pharmaceuticals is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

Gemini Therapeutics has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -48.38%. Gemini Therapeutics' return on equity of -38.78% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gemini Therapeutics	N/A	-38.78%	-35.88%
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%

75.4% of Gemini Therapeutics shares are held by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 12.9% of Gemini Therapeutics shares are held by insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Arrowhead Pharmaceuticals beats Gemini Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Gemini Therapeutics compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and Gemini Therapeutics (NASDAQ:GMTX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.

Summit Therapeutics has a beta of -1.26, meaning that its stock price is 226% less volatile than the broader market. Comparatively, Gemini Therapeutics has a beta of -0.12, meaning that its stock price is 112% less volatile than the broader market.

In the previous week, Summit Therapeutics had 1 more articles in the media than Gemini Therapeutics. MarketBeat recorded 1 mentions for Summit Therapeutics and 0 mentions for Gemini Therapeutics. Summit Therapeutics' average media sentiment score of 1.81 beat Gemini Therapeutics' score of 0.00 indicating that Summit Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Summit Therapeutics	Very Positive
Gemini Therapeutics	Neutral

Summit Therapeutics presently has a consensus price target of $26.97, indicating a potential upside of 74.92%. Given Summit Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Summit Therapeutics is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.44
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A

Gemini Therapeutics' return on equity of -38.78% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-291.24%	-243.07%
Gemini Therapeutics	N/A	-38.78%	-35.88%

4.6% of Summit Therapeutics shares are held by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are held by institutional investors. 83.5% of Summit Therapeutics shares are held by company insiders. Comparatively, 12.9% of Gemini Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Summit Therapeutics beats Gemini Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Gemini Therapeutics compare to Krystal Biotech?

Krystal Biotech (NASDAQ:KRYS) and Gemini Therapeutics (NASDAQ:GMTX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

Krystal Biotech has a beta of 0.5, meaning that its stock price is 50% less volatile than the broader market. Comparatively, Gemini Therapeutics has a beta of -0.12, meaning that its stock price is 112% less volatile than the broader market.

In the previous week, Krystal Biotech had 6 more articles in the media than Gemini Therapeutics. MarketBeat recorded 6 mentions for Krystal Biotech and 0 mentions for Gemini Therapeutics. Krystal Biotech's average media sentiment score of 0.91 beat Gemini Therapeutics' score of 0.00 indicating that Krystal Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Krystal Biotech	Positive
Gemini Therapeutics	Neutral

86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are held by institutional investors. 13.1% of Krystal Biotech shares are held by insiders. Comparatively, 12.9% of Gemini Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Krystal Biotech has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	28.41	$204.83M	$7.48	50.14
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A

Krystal Biotech has a net margin of 53.92% compared to Gemini Therapeutics' net margin of 0.00%. Krystal Biotech's return on equity of 19.25% beat Gemini Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	53.92%	19.25%	17.62%
Gemini Therapeutics	N/A	-38.78%	-35.88%

Krystal Biotech currently has a consensus target price of $340.56, indicating a potential downside of 9.20%. Given Krystal Biotech's stronger consensus rating and higher possible upside, research analysts plainly believe Krystal Biotech is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Krystal Biotech beats Gemini Therapeutics on 15 of the 15 factors compared between the two stocks.

Get Gemini Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GMTX vs. The Competition

Export

Metric	Gemini Therapeutics	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.25B	$987.25M	$6.82B	$12.56B
Dividend Yield	N/A	4.84%	2.68%	6.64%
P/E Ratio	-74.95	1.54	27.94	24.55
Price / Sales	N/A	115.89	533.88	98.03
Price / Cash	N/A	20.06	48.59	58.15
Price / Book	25.93	8.17	10.91	6.45
Net Income	-$71.87M	-$3.96M	$3.57B	$336.71M
7 Day Performance	6.51%	3.80%	3.62%	2.55%
1 Month Performance	4.14%	2.40%	4.40%	0.32%
1 Year Performance	46.59%	53.38%	35.81%	25.76%

Gemini Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GMTX Gemini Therapeutics	N/A	$74.95 +2.5%	N/A	+38.1%	$3.25B	N/A	N/A	30	High Trading Volume
RDY Dr. Reddy's Laboratories	1.5949 of 5 stars	$14.63 +2.2%	N/A	-6.0%	$11.94B	$3.58B	25.22	27,527	High Trading Volume
ELAN Elanco Animal Health	3.6595 of 5 stars	$23.96 +3.4%	$28.55 +19.2%	+66.7%	$11.58B	$4.72B	N/A	9,400	Analyst Forecast
ARWR Arrowhead Pharmaceuticals	1.8252 of 5 stars	$79.81 -0.1%	$86.36 +8.2%	+399.9%	$11.25B	$829.45M	N/A	400	Analyst Forecast
SMMT Summit Therapeutics	4.0154 of 5 stars	$14.25 flat	$27.23 +91.1%	-32.2%	$11.06B	N/A	N/A	110	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GMTX) was last updated on 7/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gemini Therapeutics (GMTX) Competitors

GMTX vs. RDY, ELAN, ARWR, SMMT, and KRYS

How does Gemini Therapeutics compare to Dr. Reddy's Laboratories?

Summary

How does Gemini Therapeutics compare to Elanco Animal Health?

Summary

How does Gemini Therapeutics compare to Arrowhead Pharmaceuticals?

Summary

How does Gemini Therapeutics compare to Summit Therapeutics?

Summary

How does Gemini Therapeutics compare to Krystal Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GMTX vs. The Competition

Gemini Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gemini Therapeutics (GMTX) Competitors

GMTX vs. RDY, ELAN, ARWR, SMMT, and KRYS

How does Gemini Therapeutics compare to Dr. Reddy's Laboratories?

Which has more risk & volatility, GMTX or RDY?

Does the media refer more to GMTX or RDY?

Do analysts prefer GMTX or RDY?

Which has higher earnings and valuation, GMTX or RDY?

Is GMTX or RDY more profitable?

Do institutionals & insiders believe in GMTX or RDY?

Summary

How does Gemini Therapeutics compare to Elanco Animal Health?

Which has more volatility & risk, GMTX or ELAN?

Do analysts prefer GMTX or ELAN?

Do insiders & institutionals believe in GMTX or ELAN?

Does the media refer more to GMTX or ELAN?

Which has preferable valuation and earnings, GMTX or ELAN?

Is GMTX or ELAN more profitable?

Summary

How does Gemini Therapeutics compare to Arrowhead Pharmaceuticals?

Does the media refer more to GMTX or ARWR?

Which has more risk and volatility, GMTX or ARWR?

Which has stronger earnings & valuation, GMTX or ARWR?

Do analysts prefer GMTX or ARWR?

Is GMTX or ARWR more profitable?

Do insiders and institutionals believe in GMTX or ARWR?

Summary

How does Gemini Therapeutics compare to Summit Therapeutics?

Which has more risk & volatility, SMMT or GMTX?

Does the media refer more to SMMT or GMTX?

Do analysts rate SMMT or GMTX?

Which has higher valuation & earnings, SMMT or GMTX?

Is SMMT or GMTX more profitable?

Do institutionals & insiders believe in SMMT or GMTX?

Summary

How does Gemini Therapeutics compare to Krystal Biotech?

Which has more volatility & risk, KRYS or GMTX?

Does the media refer more to KRYS or GMTX?

Do institutionals and insiders have more ownership in KRYS or GMTX?

Which has preferable valuation and earnings, KRYS or GMTX?

Is KRYS or GMTX more profitable?

Do analysts rate KRYS or GMTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GMTX vs. The Competition

Gemini Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools